

LEONARD GEORGE PRESTA

1900 Gough St., Apt. 206
San Francisco, CA 94109
(415) 922-2637
e-mail: leonard.presta@gmail.com

Synopsis of Experience

- More than 30 years of experience in the biotechnology industry, primarily in protein/antibody engineering.
- At Genentech, I was responsible for the protein engineering that led to a series of marketed therapeutic monoclonal antibodies - Herceptin, Raptiva, Xolair, Avastin, Lucentis, Perjeta, Ocrevus and therapeutic protein Tenecteplase.
- At Merck (formerly Schering-Plough), I was responsible for protein and antibody engineering of all internal therapeutic antibodies in the pipeline, including Ilumya (licensed to Sun Pharma).
- Published extensively in peer-reviewed journals, an inventor on 190 issued U.S. patents, and an editorial board member (past or present) for Journal of Biological Chemistry, PROTEINS, and MABS

Education:

Ph.D. Biochemistry and Biophysics, Texas A&M University, 1985
B.S. Chemistry, cum laude, University of Arizona, 1976
B.S. Biology, cum laude, University of Arizona, 1976

Research and Professional Experience:

2013-present	Consultant for over 30 scientific and legal firms
2016-2018	Zymeworks, Inc Executive Director of Protein Engineering
2007-2012	Distinguished Fellow Merck/Schering-Plough Biopharma Responsible for design and protein engineering of therapeutic antibodies and auxiliary antibodies used for animals models (e.g., murinized, cynoized antibodies) and bispecific antibodies and other new antibody formats. Total of 4 Ph.D. and 10 B.S./M.S. direct/indirect reports.
2005-2010	Editorial Board, Journal of Biological Chemistry
2001-2007	Senior Director, Protein Engineering

Schering-Plough Biopharma (formerly DNAX Research Institute)

Department responsible for generation and production of research and therapeutics proteins, primarily antibodies; includes six groups specializing in antibody generation (hybridoma/phage library), molecular biology (plasmid and vector generation), protein expression and purification, assay development, proteomics and protein engineering. Total of 8 Ph.D. and 21 B.S./M.S. direct/indirect reports.

2000-2001

Director, Antibody Technology Group
Genentech, Inc.

Generation of antibodies for use as reagents and therapeutics for Genentech Research and Development
Direct reports: one Senior Scientist, one Scientist;
total of 20 direct/indirect reports in group

1999-2001

Staff Scientist, Dept. of Immunology
Genentech, Inc.

Molecular modeling, engineering and structure-function studies on proteins, with emphasis on immunoglobulins, Fc receptors, neurotrophins and neurotrophin receptors, intercellular adhesion molecules
Direct reports: two postdoctoral positions; two Senior Research Assistants; five Research Assistants; one Scientist.

1996-1999

Senior Scientist, Dept. of Immunology
Genentech, Inc.

Molecular modeling, engineering and structure-function studies on proteins, with emphasis on immunoglobulins, Fc receptors, neurotrophins and neurotrophin receptors, intercellular adhesion molecules; two postdoctoral positions; six Research Assistants.

1993-1995

Senior Scientist, Dept. of Protein Engineering,
Genentech, Inc.

Molecular modeling, engineering and structure-function studies on proteins, with emphasis on immunoglobulins, neurotrophins and neurotrophin receptors; two postdoctoral positions; three Research Assistants.

1991-2007

Editorial Board, PROTEINS: Structure, Function, and Genetics

1988-1992

Scientist, Dept. of Protein Engineering,
Genentech, Inc.

Molecular modeling, engineering and structure-function studies on proteins, with emphasis on immunoglobulins and serine proteases; two Research Assistants.

- 1986-1988 Postdoctoral Fellow with Dr. George Rose, Dept. of Biological Chemistry, Pennsylvania State University Medical Center
Theoretical studies on protein folding; helix signals in proteins.
- 1982-1984 Lecturer, Dept. of Biochemistry and Biophysics, Texas A&M University
Teaching and coordinating undergraduate senior-level biochemistry laboratory courses with four teaching assistants and 200 students.
- 1980-1982 Teaching Assistant, Dept. of Biochemistry and Biophysics, Texas A&M University
Assisted faculty in biochemistry laboratory course.
- 1977-1980 Technical Assistant, Analytical-Organic Section, Illinois Institute of Technology Research Institute
Development of computer programs for processing gas chromatography-mass spectrometer data; studies on vapor phase hydrolysis of chloroacetyl chlorides (air pollution).

Doctoral Dissertation:

Interactive Computer Graphics Modeling and Molecular Mechanics Calculations of Protein-Ligand Interactions. Studies of the interaction of peptide and non-peptide substrates and inhibitors with serine proteases by computer modeling, molecular mechanics calculations and X-ray crystallography.

Publications: 85

O'Brien, N.A. et al. *Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-drug Conjugate for Treatment of CLDN18.2 Positive Cancers* **Mol. Cancer Ther.** 22:1365 (2023)

McDermott, M.S.J. et al. *Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors* **Clinical Cancer Research** 29:2131 (2023)

Weisser, N.E. et al. *An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity* **Nature Commun.** 14:1394 (2023)

Gerber, H.-P., Presta, L.G. *TCR mimic compounds for pHLA targeting with high potency modalities in oncology* **Frontiers In Oncology** 12:1027548 (2022)

Murphy, J.T., Burey, A.P., Beebe, A.M., Gu, D., Presta, L.G., Merghoub, T., Wolchok, J.D. *Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice.* **Blood** 123:2172-2180 (2014)

Lu, Y, Vernes, J.M., Chiang, N., Ou, Q., Ding, J., Adams, C., Hong, K., Truong, B.T., Ng, D., Shen, A., Nakamura, G., Gong, Q., Presta, L.G., Beresini, M., Kelley, B., Lowman, H., Wong, W.L., Meng, Y.G. *Identification of IgG(1) variants with increased affinity to FcγRIIIA and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.* **J. Immunol. Methods** 365:132-141 (2011)

Presta, L.G. *Molecular engineering and design of therapeutic antibodies.* **Curr. Opin. Immunol.** 20:460-470 (2008)

Presta, L. *Evolving an anti-toxin antibody.* **Nat. Biotechnol.** 25:63-65 (2007)

Chen, Y., Langrish, C.L., McKenzie, B., Joyce-Shaikh, B., Stumhofer, J.S., McClanahan, T., Blumenschein, W., Churakova, T., Low, J., Presta, L., Hunter, C.A., Kastelein, R.A., Cua, D.J. *Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis.* **J. Clin. Invest.** 116:1317-1326 (2006)

Petkova, S.B., Akilesh S., Sproule T.J., Christianson, G.J., Al Khabbaz, H., Brown, A.C., Presta, L.G., Meng, Y.G., Roopenian D.C. *Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.* **Intl. Immunol.** 18:1759-1769 (2006)

Presta, L.G. *Engineering of therapeutic antibodies to minimize immunogenicity and optimize function.* **Adv. Drug Delivery Rev.** 58:640-656 (2006)

Adams, C.W., Allison, D.E., Flagella, K., Presta, L., Clarke, J., Dybdal, N., McKeever, K., Sliwkowski, M.X. *Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab.* **Cancer Immunol. Immunother.** 55:717-727 (2006)

Presta, L.G. *Selection, design, and engineering of therapeutic antibodies.* **J. Allergy Clin. Immunol.** 116:731-736 (2005)

Wang, Y., Hailey, J., Williams, D., Wang, Y., Lipari, P., Malkowski, M., Wang, X., Xie, L., Li, G., Saha, D., Ling, W.L., Cannon-Carlson, S., Greenberg, R., Ramos, R.A., Shields, R., Presta, L., Brams, P., Bishop, W.R., Pachter, J.A. *Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody.* **Mol. Cancer Ther.** 4:1214-1221 (2005)

Hong, K., Presta, L.G., Lu, Y., Penn, A., Adams, C., Chuntharapai, A., Yang, J., Wong, W.L., Meng, Y.G. *Simple quantitative live cell and anti-idiotypic antibody based ELISA for humanized antibody directed to cell surface protein CD20.* **J. Immunol. Meth.** 294:189-197 (2004)

Presta, L. *Antibody engineering for therapeutics.* **Curr. Opin. Struct. Biol.** 13:519-525 (2003)

Eigenbrot, C., Meng, Y.G., Krishnamurthy, R., Lipari M.T., Presta, L., Devaux, B., Wong, T., Moran, P., Bullens, S., Kirchhofer, D. *Structural insight into how an anti-idiotypic antibody against D3H44 (anti-tissue factor antibody) restores normal coagulation.* **J. Mol. Biol.** 331:433-446 (2003)

Miller, K., Meng, G., Liu, J., Hurst, A., Hsei, V., Wong, W-L., Ekert, R., Lawrence, D., Sherwood, S., DeForge, L., Gaudreault, J., Keller, G., Sliwkowski, M., Ashkenazi, A., Presta, L. *Design, construction, and in vitro analyses of multivalent antibodies.* **J. Immunol.** 170:4854-4861 (2003)

Presta, L.G. *Celebrating diversity and mimicking maturation.* **Nat. Biotechnol.** 20:1096-1097 (2002)

Presta, L.G., Shields R.L. *Understanding the binding of IgE to its high-affinity receptor and to an anti-IgE antibody.* In: *IgE and Anti-IgE Therapy in Asthma and Allergic Disease*, Fick, R.B.Jr. & Jardieu, P.M. (eds.), Dekker, New York, 2002, pp.23-38

Presta, L.G., Shields, R.L., Namenuk, A.K., Hong, K., Meng, Y.G. *Engineering therapeutic antibodies for improved function.* **Biochem. Soc. Trans.** 30:487-490 (2002)

Presta, L.G. *Engineering antibodies for therapy.* **Curr. Pharm. Biotechnol.** 3:237-256 (2002)

Vajdos, F.F., Adams, C.W., Breece, T.N., Presta, L.G., de Vos, A.M., Sidhu, S.S. *Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis.* **J. Mol. Biol.** 320:415-428 (2002)

Shields, R.L., Lai, J., Keck, R., O'Connell, L.Y., Hong, K., Meng, Y.G., Weikert, S.H.A., Presta, L.G. *Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity.* **J. Biol. Chem.** 277:26733-26740 (2002)

Gadek, T.R., Burdick, D.J., McDowell, R.S., Stanley, M.S., Marsters J.C. Jr., Paris, K.J., Oare, D.A., Reynolds, M.E., Ladner, C., Zioncheck, K.A., Lee, W.P., Gribbling, P., Dennis,

M.S., Skelton, N.J., Tumas, D.B., Clark, K.R., Keating, S.M., Beresini, M.H., Tilley, J.W., Presta, L.G., Bodary, S.C. *Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunomodulatory epitope to a small molecule.* **Science** 295:1086-1089 (2002)

Faelber, K., Kirchhofer, D., Presta, L., Kelley, R.F., Muller, Y.A. *The 1.85 Å resolution crystal structures of tissue factor in complex with humanized Fab D3H44 and of free humanized Fab D3H44: revisiting the solvation of antigen combining sites.* **J. Mol. Biol.** 313:83-97 (2001)

Leong, S.R., DeForge, L., Presta, L., Gonzalez, T., Fan, A., Reichert, M., Chuntharapai, A., Kim, J.K., Tumas, D.B., Lee, W.P., Gribling, P., Snedecor, B., Chen, H., Hsei, V., Schoenhoff, M., Hale, V., Deveney, J., Koumenis, I., Shahrokh, Z., McKay, P., Galan, W., Wagner, B., Narindray, D., Hebert, C., Zapata, G. *Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-directed pegylation.* **Cytokine** 16:106-119 (2001)

Chuntharapai, A., Lai, J., Huang, X., Gibbs, V., Kim, K.J., Presta, L.G., Stewart, T.A. *Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM and SLE.* **Cytokine** 15:250-260 (2001)

Shields, R.L., Namenuk, A.K., Hong, K., Meng, Y.G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., Fox, J.A., Presta, L.G. *High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII and FcRn and design of IgG1 variants with improved binding to the FcγR.* **J. Biol. Chem.** 276:6591-6604 (2001)

Presta, L., Sims, P., Meng, Y.G., Moran, P., Bullens, S., Bunting, S., Schoenfeld, J., Lowe, D., Lai, J., Rancatore, P., Iverson, M., Lim, A., Chisholm, V., Kelley, R.F., Riederer, M., Kirchhofer, D. *Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic.* **Thrombosis & Haemostasis** 85:379-389 (2001)

Idusogie, E.E., Wong, P.Y., Presta, L.G., Gazzano-Santoro, H., Totpal, K., Ultsch, M., Mulkerrin, M.G. *Engineered antibodies with increased activity to recruit complement.* **J. Immunol.** 166:2571-2575 (2001)

Poston, R.S., Robbins, R.C., Chan, B., Simms, P., Presta, L., Jardieu, P., Morris, R.E. *Effects of humanized monoclonal antibody to rhesus CD11a in rhesus monkey cardiac allograft recipients.* **Transplantation** 69:2005-2013 (2000)

Idusogie, E.E., Presta, L.G., Gazzano-Santoro, H., Totpal, K., Wong, P.Y., Ultsch, M., Meng, Y.G., Mulkerrin, M.G. *Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc.* **J. Immunol.** 164:4178-4184 (2000)

Clynes, R.A., Towers, T.L., Presta, L.G., Ravetch, J.V. *Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.* **Nature Medicine** 6:443-446 (2000)

O'Connell, L.; Hongo, J.-A.; Presta, L.G.; Tsoulfas, P. *TrkA amino acids controlling specificity for nerve growth factor.* **J. Biol. Chem.** 275:7870-7877 (2000)

Edwards, C.P.; Fisher, K.L.; Presta, L.G.; Bodary, S.C. *Mapping the intercellular adhesion molecule-1 and -2 binding site on the inserted domain of leukocyte function-associated antigen-1.* **J. Biol. Chem.** 273:28937-28944 (1998)

Merchant, A.M.; Zhu, Z.; Yuan, J.Q.; Goddard, A.; Adams, C.W.; Presta, L.G.; Carter, P. *An efficient route to human bispecific IgG.* **Nature Biotechnology** 16:677-681 (1998)

O'Connor, S.J.; Meng, Y.G.; Presta, L.G. *Humanization of an antibody against human protein C and calcium-dependence involving framework residues.* **Protein Engineering** 11:321-328 (1998)

Urfer, R.; Tsoulfas, P.; O'Connell, L.; Hongo, J.-A.; Zhao, W.; Presta, L.G. *High resolution mapping of the binding site of trkA for nerve growth factor and trkC for neurotrophin-3 on the second immunoglobulin-like domain of the trk receptors.* **J. Biol. Chem.** 273:5829-5840 (1998).

Davis-Smyth, T., Presta, L.G., Ferrara, N. *Mapping the charged residues in the second immunoglobulin-like domain of the vascular endothelial growth factor/placenta growth factor receptor Flt-1 required for binding and structural stability.* **J. Biol. Chem.** 273:3216-3222 (1998)

Presta, L.G.; Chen, H.; O'Connor, S.J.; Chisolm, V.; Meng, G.Y.; Krummen, L.; Winkler, M.; Ferrara, N. *Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.* **Cancer Research** 57:4593-4599 (1997).

Fong, S.; Jones, S.; Renz, M.E.; Chiu, H.H.; Ryan, A.M.; Presta, L.G.; Jackson, D. *Mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Its binding motif for $\alpha 4\beta 7$ and role in experimental colitis.* **Immunologic Res.** 16:299-311 (1997).

Pearce, K.H. Jr.; Potts, B.J.; Presta, L.G.; Bald, L.N.; Fendly, B.M.; Wells, J.A. *Mutational analysis of thrombopoietin for identification of receptor and neutralizing antibody sites.* **J. Biol. Chem.** 272:20595-20602 (1997).

Urfer, R.; Tsoulfas, P.; O'Connell, L.; Presta, L.G. *Specificity determinants in neurotrophin-3 and the design of nerve growth factor-based trkC agonists by changing*

central β -strand bundle residues to their neurotrophin-3 analogs. **Biochemistry** 36:4775-4781 (1997).

Zhu, Z.; Presta, L.G.; Zapata, G.; Carter, P. *Remodeling domain interfaces to enhance heterodimer formation.* **Prot. Sci.** 6:781-788 (1997).

Baca, M.; Presta, L.G.; O'Connor, S.J.; Wells, J.A. *Antibody humanization using monovalent phage display.* **J. Biol. Chem.** 272:10678-10684 (1997).

Fisher, K.L.; Lu, J.; Riddle, L.; Kim, K.J.; Presta, L.G.; Bodary, S.C. *Identification of the binding site in intercellular adhesion molecule 1 for its receptor, leukocyte function-associated antigen-1.* **Mol. Biol. Cell** 8:501-515 (1997).

Saban, R.; Haak-Frendscho, M.; Zine, M.; Presta, L.G.; Bjorling, D.E.; Jardieu, P. *Human anti-IgE monoclonal antibody blocks passive sensitization of human and rhesus monkey bladder.* **J. Urol.** 157:689-693 (1997).

Werther, W.W.; Gonzalez, T.N.; O'Connor, S.J.; McCabe, S.; Chan, B.; Hotaling, T.; Champe, M.; Fox, J.A.; Jardieu, P.M.; Berman, P.W.; Presta, L.G. *Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1.* **J. Immunol.** 157:4986-4995 (1996).

Viney, J.L.; Jones, S.; Chui, H.H.; Lagrimas, B.; Renz, M.E.; Presta, L.G.; Jackson, D.; Hillan, K.J.; Lew, S.; Fong, S. *Mucosal addressin cell adhesion molecule-1. A structural and functional analysis demarcates the integrin binding motif.* **J. Immunol.** 157:2488-2497 (1996)

Davis-Smyth, T.; Chen, H.; Park, J.; Presta, L.G.; Ferrara, N. *The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade.* **EMBO J.** 15:4919-4927 (1996)

Ridgway, J.B.B.; Presta, L.G.; Carter, P. *Knobs-in-holes engineering of antibody CH3 domains for heavy chain heterodimerization.* **Protein Engineering** 9:617-621 (1996)

Binnerts, M.; van Kooyk, Y.; Edwards, C.P.; Champe, M.; Presta, L.; Bodary, S.C.; Figdor, C.G.; Berman, P.W. *Antibodies that selectively inhibit LFA-1 binding to ICAM-3 recognize a unique epitope within the CD11A I-domain.* **J. Biol. Chem.** 271:9962-9968 (1996)

Cacia, J.; Keck, R.; Presta, L.G.; Frenz, J. *Isomerization of an aspartic acid residue in the complementarity-determining region of a recombinant antibody to human IgE: identification and effect on binding affinity.* **Biochemistry** 35:1897-1903 (1996)

Chiu, H.H.; Crowe, D.T.; Renz, M.E.; Presta, L.G.; Jones, S.; Weissman, I.L.; Fong, S. *Similar but nonidentical amino acid residues on vascular cell adhesion molecule-1 are involved in the interaction with $\alpha 4\beta 1$ and $\alpha 4\beta 7$ under different activity states.* **J. Immunol.** 155:5257-5267 (1995)

Edwards, C.P.; Champe, M.; Gonzalez, T.; Wessinger, M.E.; Spencer, S.A. Presta, L.G.; Berman, P.W.; Bodary, S.C. *Identification of amino acids in the CD11A I-domain important for binding of the leukocyte function-associated antigen-1 (LFA-1) to intercellular adhesion molecule-1.* **J. Biol. Chem.** 270:12635-12640 (1995)

Shields, R.L.; Werther, W.R.; Zioncheck, K.; O'Connell, L.; Klassen, T.; Fendly, B.; Presta, L.G.; Jardieu, P.M. *Anti-IgE monoclonal antibodies that inhibit allergen-specific histamine release.* **Intl. Arch. Allergy Immunol.** 107:412-413 (1995)

Shields, R.L.; Werther, W.R.; Zioncheck, K.; O'Connell, L.; Fendly, B.; Presta, L.G.; Thomas, D.; Saban, R.; Jardieu, P. *Inhibition of allergic reactions with antibodies to IgE.* **Intl. Arch. Allergy Immunol.** 107:308-312 (1995)

Zhukovsky, E.A.; Mulkerrin, M.G.; Zitzewitz, J.A.; Presta, L.G. *The N-capping box affects global protein folding in human growth hormone.* **Protein Engineering** 8S:103-103 (1995)

Urfer, R.; Tsoulfas, P.; O'Connell, L.; Shelton, D.L.; Parada, L.F.; Presta, L.G. *An immunoglobulin-like domain determines the specificity of neurotrophin receptors.* **EMBO J.** 14:2795-2805 (1995)

Rodrigues, M.L.; Presta, L.G.; Kotts, C.E.; Wirth, C.; Mordenti, J.; Osaka, G.; Wong, W.L.T.; Nuijens, A.; Blackburn, B.; Carter, P. *Development of a humanized disulfide-stabilized anti-p185^{HER2} Fv- β -lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug.* **Cancer Res.** 55:63-70 (1995)

Urfer, R.; Tsoulfas, P.; Soppet, D.; Escandon, E.; Parada, L.F.; Presta, L.G. *The binding epitopes of neurotrophin-3 to its receptors *trkC* and *gp75* and the design of a multifunctional human neurotrophin.* **EMBO J.** 13:5896-5909 (1994)

Saban, R., Haak-Frendscho, M.; Zine, M.; Ridgway, J.; Gorman, C.; Presta, L.G.; Bjorling, S.; Saban, M.; Jardieu, P. *Human FcεRI-IgG and humanized anti-IgE monoclonal antibody MaE11 block passive sensitization of human and rhesus monkey lung.* **J. Allergy Clin. Immunol.** 94:836-843 (1994)

Lasky, L.A.; Presta, L.G.; Erbe, D.V. *Structure-function aspects of selectin-carbohydrate interactions.* in **Cellular Adhesion. Molecular Definition to Therapeutic Potential**, (Metcalf, B.W.; Dalton, B.J.; Poste, G., eds.) Plenum Press, New York, pp. 37-53 (1994)

Presta, L.G.; Shields, R.; O'Connell, L.; Lahr, S.; Porter, J.; Gorman, C.; Jardieu P. *The binding site on human immunoglobulin E for its high affinity receptor.* **J. Biol. Chem.** 269:26368-26373 (1994)

Presta, L. *Humanized Monoclonal Antibodies* in **Annual Reports In Medicinal Chemistry**, (Bristol, J.A., ed.) Academic Press, San Diego, 29:317-324 (1994)

Zhukovsky, E.A.; Mulkerrin, M.G.; Presta, L.G. *Contribution to global protein stabilization of the N-capping box in human growth hormone.* **Biochemistry** 33:9856-9864 (1994)

Renz, M. E.; Chiu, H. H.; Jones, S.; Fox, J.; Kim, J. K.; Presta, L. G.; Fong, S. *Structural requirements for adhesion of soluble recombinant murine Vascular Cell Adhesion Molecule-1 to α4β1.* **J. Cell Biol.** 125:1395-1406 (1994)

Lokker, N.; Presta, L. G.; Godowski, P. *Mutational analysis and molecular modeling of the N-terminal kringle-containing domain of hepatocyte growth factor identifies amino acid side chains important for interaction with the c-Met receptor.* **Protein Engineering** 7:895-903 (1994)

Presta, L.G.; Lahr, S. J.; Shields, R. L.; Porter, J. P.; Gorman, C.M.; Fendly, B. M.; Jardieu, P. M. *Humanization of an antibody directed against immunoglobulin E.* **J. Immunology** 151:2623-2632 (1993)

Kelley, R.F.; O'Connell, M.P.; Carter, P.; Presta, L.; Eigenbrot, C.; Covarrubias, M.; Snedecor, B.; Speckart, R.; Blank, G.; Vetterlein, D.; Kotts, C. *Characterization of humanized anti-p185^{HER2} antibody Fab fragments produced in Escherichia coli.* in **Protein Folding: In Vivo and In Vitro** (Cleland, J.L., ed.) Am. Chem. Soc. Symp. Series 526:218-239 (1993)

Erbe, D.V.; Watson, S.R.; Presta, L.G.; Wolitzky, B.A.; Foxall, C.; Brandley, B.K.; Lasky, L.A. *P- and E-selectin use common sites for carbohydrate ligand recognition and cell adhesion.* **J. Cell Biol.** 120:1227-1235 (1993)

- Rodrigues, M.L.; Shalaby, M.R.; Werther, W.; Presta, L.; Carter, P. *Engineering a humanized bispecific F(ab')₂ fragment for improved binding to T cells*. **Intl. J. Cancer**, S7:45-50 (1992)
- Eigenbrot, C.; Randal, M.; Presta, L.G.; Carter, P.; Kossiakoff, A.A. *X-ray structures of the antigen-binding domains from three variants of humanized anti-p185^{HER2} antibody 4D5 and comparison with molecular modeling*. **J. Mol. Biol.** 229:969-995 (1993)
- Erbe, D.V.; Wolitzky, B.A.; Presta, L.G.; Norton, C.R.; Ramos, R.J.; Burns, D.K.; Rumberger, J.M.; Rao, B.N.N.; Foxall, C.; Brandley, B.K.; Lasky, L.A. *Identification of an E Selectin region critical for carbohydrate recognition and cell adhesion*. **J. Cell Biol.** 119:215-227 (1992)
- Kelley, R.F.; O'Connell, M.P.; Carter, P.; Presta, L.; Eigenbrot, C.; Covarrubias, M.; Snedecor, B.; Bourell, J.H.; Vetterlein, D. *Antigen binding thermodynamics and anti-proliferative effects of chimeric and humanized anti-p185^{HER2} antibody F_{ab} fragments*. **Biochemistry** 31:5434-5441 (1992)
- Stickle, D.F.; Presta, L.G.; Dill, K.A.; Rose, G.D. *Hydrogen bonding in globular proteins*. **J. Mol. Biol.** 226:1143-1159 (1992)..
- Carter, P.C.; Presta, L.G.; Gorman, C.M.; Ridgway, J.B.B.; Henner, D.; Wong, W.L.T.; Rowland, A.M.; Kotts, C.; Carver, M.E.; Shepard, H.M. *Humanization of an anti-p185^{HER2} antibody for human cancer therapy*. **Proc. Natl. Acad. Sci. USA** 89:4285-4289 (1992)
- Presta, L.G. *Antibody Engineering*. **Current Opinion in Structural Biology**. 2:593-596 (1992) & **Current Opinion in Biotechnology**. 2:394-398 (1992)
- Kossiakoff, A.A.; Sintchak, M.D.; Shpungin, J.; Presta, L.G. *Analysis of solvent structure in proteins using neutron D₂O-H₂O solvent maps: pattern of primary and secondary hydration of trypsin*. **Proteins** 12:223-236 (1992)
- Shalaby, M.R.; Shepard H.M.; Presta, L.G.; Rodrigues, M.; Beverley, P.C.L.; Feldmann, M.; Carter, P. *The development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing HER2 proto-oncogene*. **J. Exp. Med.** 175:217-225 (1992)
- Bennett, W.F.; Paoni, N.F.; Keyt, B.A.; Botstein, D.; Jones, A.J.S.; Presta, L.; Wurm, F.M.; Zoller, M.J. *High resolution analysis of functional determinants on human tissue-type plasminogen activator*. **J. Biol. Chem.** 266:5191-5201 (1991)

Ashkenazi, A.; Presta, L.G.; Marsters, S.A.; Camerato, T.R.; Rosenthal, K.A.; Fendly, B.M.; Capon, D.J. *Mapping the CD4 binding site for human immunodeficiency virus by alanine-scanning mutagenesis*. **Proc. Natl. Acad. Sci. USA** 87:7150-7154 (1990)

Presta, L.G. *Protein structure analysis and development of databases*. **Protein Engineering** 2:395-397 (1989)

Presta, L.G.; Rose, G.D. *Helix signals in proteins* in **Protein Folding: Deciphering the Second Half Of The Genetic Code** (Gierasch, L.M. & King, J., eds.) Am. Assoc. Adv. Sci., Washington D.C., pp. 29-43 (1989)

Presta, L.G.; Rose, G.D. *Helix signals in proteins*. **Science**, 240: 1632-1641 (1988)

Presta, L.G.; Meyer Jr., E.F. *Prediction of protein-ligand interactions: the complex of porcine pancreatic elastase with a valine-derived benzoxazinone*. **Biopolymers** 26:1207-1225 (1987)

Radhakrishnan, R.; Presta, L.G.; Meyer Jr, E.F.; Wildonger, R. *Crystal structures of the complex of porcine pancreatic elastase with two valine-derived benzoxazinone inhibitors*. **J. Mol. Biol.** 198:417-424 (1987)

Meyer Jr, E.F.; Presta, L.G. *The modeling and verification of complexes of elastase and other serine proteases* in **Topics In Molecular Pharmacology. Vol. 3 Molecular Graphics And Drug Design** (Burgen, A.S.V., Roberts, G.C.K. & Tute, M.S., eds.), Elsevier, New York, pp.307-321 (1986)

Meyer Jr., E.F.; Radhakrishnan, R.; Cole, G.M.; Presta, L.G. *Structure of the product complex of Acetyl-Ala-Pro-Ala with porcine pancreatic elastase at 1.65Å resolution*. **J. Mol. Biol.** 189:533-539 (1986)

Meyer Jr, E.F.; Presta, L.G.; Radhakrishnan, R. *The stereospecific reaction of 3-methoxy-4-chloro-7-aminoisocoumarin with crystalline porcine pancreatic elastase*. **J. Am. Chem. Soc.** 107:4091-4093 (1985)

Meyer Jr., E.F.; Cole, G.M.; Presta, L.G.; Rosenfield Jr., R.E.; Swanson, S.M. *Modeling the binding of small molecules to proteins* in **Structure Of Complexes Between Biopolymers And Low Molecular Weight Molecules** (Bartmann, W.; Snatzke, G., eds) John Wiley & Sons, New York, pp. 77-105 (1982)

U.S. Patents Issued (204)

Patent #12,065,491 August 20, 2024
Anti-TREM1 antibodies and related methods
C Chan, A Pal, V Sriram, LG Presta, TT Le, L Liang

Patent #11,873,339 January 16, 2024
Anti-C10orf54 antibodies and uses thereof
J Lippincott, ETH van der Horst, SY Kim, LG Presta, J-W Theunissen

Patent #11,795,220 October 24, 2023
Anti-PVRIG antibodies and methods of use
M White, S Kumar, C Chan, S Liang, L Stapleton, AW Drake, Y Gozlan, I Vaknin, S Sameah-Greenwald, L Dassa, Z Tiran, GS Cojocar, L Presta, R Theolis

Patent #11,701,424 July 18, 2023
Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
M White, S Kumar, C Chan, S Liang, L Stapleton, AW Drake, Y Gozlan, I Vaknin, S Sameah-Greenwald, L Dassa, Z Tiran, GS Cojocar, M Kotturi, H-Y Cheng, K Hansen, DN Giladi, E Sasfyon, E Ophir, L Presta, R Theolis, R Desai, P Wall

Patent #11,692,038 July 4, 2023
Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
LL McGrath, F Depis, C Hu, LG Presta, JA Bugge

Patent #11,639,389 May 2, 2023
Binding molecules with modified J-chain
BA Keyt, LG Presta, R Baliga

Patent #11,623,955 April 11, 2023
Anti-PVRIG antibodies and methods of use
M White, S Kumar, C Chan, S Liang, L Stapleton, AW Drake, Y Gozlan, I Vaknin, S Sameah-Greenwald, L Dassa, Z Tiran, GS Cojocar, L Presta, R Theolis

Patent #11,572,407 Feb 7, 2023
Anti-MARCO antibodies and uses thereof
N Jahchan, M Streuli, X Yang, L Liang, V Sriram, J Pollack, K Mojica, V Juric, L Haegblom, LG Presta, S Mitra

Patent #11,555,075 Jan 17, 2023
Modified J-chain
BA Keyt, LG Presta, F Zhang, R Baliga

Patent #11,542,342 Jan 3, 2023
Binding molecules with modified J-chain
BA Keyt, LG Presta, R Baliga

Patent #11,530,247 Dec 20, 2022
Single-chain TNF Receptor 2 agonist fusion proteins
DC Foster, LB Giebel, LG Presta

Patent #11,505,602 Nov 22, 2022
Anti-TREM2 antibodies and related methods
M Streuli, V Sriram, A Pal, LG Presta

Patent #11,359,025 June 14, 2022
Anti-IL1-RAP antibodies
YP Jiang, JR Junutula, LG Presta

Patent #11,299,551 April 12, 2022
Composite binding molecules targeting immunosuppressive B cells
L Presta, P Tumeh, N Lonberg, O Duramad

Patent #11,230,608 January 25, 2022
Anti-glycan antibodies and uses thereof
L Presta, T Liang, J Chang

Patent #11,220,542 January 11, 2022
Anti-PVRIG antibodies and methods of use
M White, S Kumar, C Chan, S Liang, L Stapleton, DW Drake, Y Gozlan, I Vaknin,
S Sameah-Greenwald, L Dassa, Z Tiran, GS Cojocar, L Presta, R Theolis

Patent #11,208,495 December 28, 2021
Anti-TM4SF1 antibodies and methods of using same
PA Jaminet, S-C Jaminet, HF Dvorak, LG Presta,

Patent #11,174,306 November 16, 2021
Chimeric antigen receptor effector cell switches with humanized targeting moieties and/
or optimized chimeric antigen receptor interacting domains and uses thereof
TS Young, L Presta, D Rodgers, E Hampton, T Wright, PG Schultz, E Laborda, E
Khialeeva, S Viaud

Patent #11,161,915 November 2, 2021
Antigen-binding polypeptide constructs comprising kappa and lambda light chains and
uses thereof
D Urosev, SAL Tom-Yew, LG Presta, M Sanches

Patent #11,147,886 October 19, 2021
Drug-conjugated bispecific antigen-binding constructs
GYK Ng, LG Presta, T Spreter Von Kreudenstein

Patent #11,091,546 August 17, 2021
Optimized PNE-based chimeric receptor T cell switches and uses thereof
T Young, DT Rodgers, I Hardy, C Kim, PG Schultz, E Hampton, E Laborda, L Presta

Patent #11,072,662 July 27, 2021
Humanized anti-CLL-1 antibodies
Y-P Jiang, JR Junutula, LG Presta, N Tsurushita

Patent #11,028,182 June 8, 2021
Antigen-binding constructs targeting HER2
E Escobar-Cabrera, LG Presta,

Patent #10,975,147 April 13, 2021
Modified J-chain
B Keyt, LG Presta, F Zhang, R Baliga

Patent #10,954,302 March 23, 2021
Anti-PD-L1 antibodies
B Keyt, LG Presta, R Baliga

Patent #10,927,172 February 23, 2021
Caninized murine antibodies to human PD-1
M Morsey, Y Zhang, D Bartels-Morozov, J Erskine, I Tarpey, L Presta

Patent #10,836,828 November 17, 2020
Anti-TREM-1 antibodies and related methods
C Chan, A Pal, V Sriram, LG Presta, TT Le, L Liang

Patent #10,822,399 November 3, 2020
IgA multi-specific binding molecules
BA Keyt, LG Presta, F Zhang; SF Carroll

Patent #10,766,959 September 8, 2020
Anti-C10ORF54 antibodies and uses thereof
J Lippincott, ETH van der Horst, SY Kim, LG Presta, J-W Theunissen

Patent #10,751,415 August 25, 2020
Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof

M White, et al.

Patent #10,618,978 April 14, 2020
Binding molecules with modified J-chain
BA Keyt, LG Presta, R Baliga

Patent #10,556,959 February 11, 2020
Anti-CD39 antibodies and uses thereof
G Chen, GM Hayes, J-W Theunissen, ETH van der Horst; LG Presta

Patent #10,508,148 December 17, 2019
Anti-TREM2 antibodies and related methods
M Streuli, V Sriram, A Pal, LG Presta

Patent #10,421,818 September 24, 2019
Anti-C10orf54 antibodies and uses thereof
J Lippincott, ETH van der Horst, SY Kim, LG Presta

Patent #10,414,823 September 17, 2019
Anti-C10orf54 antibodies and uses thereof
J Lippincott, ETH van der Horst, SY Kim, LG Presta

Patent #10,400,040 September 3, 2019
Anti-GITR antibodies
XM Schebye, GP Ermakov, DJ Hodges, LG Presta

Patent #10,400,038 September 3, 2019
Modified J-chain
B Keyt, LG Presta, F Zhang, R Baliga

Patent #10,351,631 July 16, 2019
Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
BA Keyt, F Zhang, LG Presta, R Yoshimura

Patent #10,351,625 July 16, 2019
Anti-PVRIG antibodies and methods of use
M White, S Kumar, C Chan, S Liang, L Stapleton, AW Drake, Y Gozlan, I Vaknin, S Sameah-Greenwald, L Dassa, Z Tiran, GS Cojocaru, L Presta, R Theolis

Patent #10,227,408 March 12, 2019
Anti-PVRIG antibodies and methods of use
M White, S Kumar, C Chan, S Liang, L Stapleton, AW Drake, Y Gozlan, I Vaknin, S Sameah-Greenwald, L Dassa, Z Tiran, GS Cojocaru, L Presta, R Theolis

Patent #10,213,505 February 26, 2019
Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
M White et al.

Patent #10,124,061 November 13, 2018
Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
M White et al.

Patent #10,100,123 October 16, 2018
Anti-C10orf54 antibodies and uses thereof
J Lippincott, ETH van der Horst, SY Kim, LG Presta

Patent #10,023,636 July 17, 2018
Caninized murine antibodies to PD-1
M Morsey, Y Zhang, D Bartels-Morozov, J Erskine, I Tarpey, LG Presta

Patent #9,951,134 April 24, 2018
Modified J-chain
B Keyt, LG Presta, F Zhang, R Baliga

Patent #9,809,648 November 7, 2017
Engineered anti-IL-23p19 antibodies
LG Presta, BM Beyer, RN Ingram, PK Orth, Y-H Liu

Patent #9,714,289 July 25, 2017
Anti-PVRIG antibodies and methods of use
M White, S Kumar, C Chan, S Liang, L Stapleton, AW Drake, Y Gozlan, I Vaknin, S Sameah-Greenwald, L Dassa, Z Tiran, GS Cojocaru, L Presta, R Theolis

Patent #9,701,751 July 11, 2017
Anti-GITR antibodies
XM Shebye, GP Ermakov, DJ Hodges, LG Presta

Patent #9,493,579 November 15, 2016
Multivalent antibodies and uses therefor
KL Miller, LG Presta

Patent #9,409,989 August 9, 2016
Method for making multispecific antibodies having heteromultimeric and common components
WR Arathoon, PJ Carter, AM Merchant, LG Presta

Patent #9,273,113 March 1, 2016
Methods of inhibiting vascular endothelial growth factor activity
TL Davis-Smyth, HH Chen, L Presta, N Ferrara

Patent #8,765,412 July 1, 2014
Method for making multispecific antibodies having heteromultimeric and common components
WR Arathoon, PJ Carter, AM Merchant, LG Presta

Patent #8,753,843 June 17, 2014
Antibodies to IL-17A
LG Presta, EP Bowman

Patent #8,722,859 May 13, 2014
Multivalent antibodies and uses therefor
KL Miller, LG Presta

Patent # 8,709,424 April 29, 2014
Anti-GITR antibodies
XM Schebye, GP Ermakov, DJ Hodges, LG Presta

Patent # 8,691,532 April 8, 2014
Nucleic acids encoding engineered anti-IL-23R antibodies
LG Presta

Patent # 8,679,785 March 25, 2014
Knobs and holes heteromeric polypeptides
PJ Carter, LG Presta, JB Ridgway

Patent # 8,674,083 March 18, 2014
Polypeptide variants with altered effector function
L Presta

Patent # 8,642,745 Feb 4, 2014
Method for making multispecific antibodies having heteromultimeric and common components
WR Arathoon, PJ Carter, AM Merchant, LG Presta

Patent # 8,637,019 Jan 28, 2014
Engineered anti-TSLP antibody
LG Presta

Patent #8,624,013 Jan 7, 2014

Interleukin-10 antibodies
LG Presta

Patent # 8,580,938 Nov 12, 2013
Engineered anti-TSLP antibody
LG Presta, R de Waal Malefyt

Patent # 8,562,992 Oct 22, 2013
Immunoglobulin variants and uses thereof
CW Adams, AC Chan, CW Crowley, HB Lowman, GR Nakamura, LG Presta

Patent # 8,557,967 Oct 15, 2013
Anti-interferon-alpha antibodies
A Chuntharapai, JK Kim, LG Presta, T Stewart

Patent # 8,524,217 Sept 3, 2013
MCP1-Ig fusion variants
LG Presta, C-C Chou

Patent # 8,513,389 Aug 20, 2013
Engineered anti-IL-23p19 antibodies
LG Presta, BM Beyer, RN Ingram, P Orth, Y-H Liu

Patent # 8,512,705 Aug 20, 2013
Engineered anti-TSLP antibody
LG Presta, R de Waal Malefyt

Patent # 8,492,531 July 23, 2013
Nucleic acids encoding humanized anti-CD40 antibodies
LG Presta, LY O'Connell

Patent # 8,475,793 July 2, 2013
Engineered anti-TSLPR antibodies
R De Waal Malefyt, LG Presta

Patent # 8,404,813 March 26, 2013
Engineered anti-IL-23p19 antibodies
LG Presta

Patent # 8,362,212 Jan 29, 2013
Engineered anti-IL23 antibodies
LG Presta

Patent # 8,349,331 Jan 8, 2013
Anti-interferon-alpha antibodies
A Chuntharapai, JK Kim, LG Presta, T Stewart

Patent # 8,303,085 Nov 13, 2012
LG Presta
Engineered anti-IL23R antibodies

Patent # 8,303,955 Nov 6, 2012
LG Presta, LY O'Connell, SO Doronina
Humanized anti-CD40 antibodies and their methods of use

Patent # 8,293,883 Oct 23, 2012
Engineered anti-IL-23p19 antibodies
LG Presta

Patent # 8,273,353 Sept 25, 2012
Inhibitors of vascular endothelial growth factor activity
TL Davis-Smyth, HH Chen, LG Presta, N Ferrara

Patent # 8,268,591 Sept 18, 2012
Compositions and methods for producing inhibitors of vascular endothelial growth factor activity
TL Davis-Smyth, HH Chen, LG Presta, N Ferrara

Patent # 8,268,313 Sept 18, 2012
Methods for using inhibitors of vascular endothelial growth factor activity
TL Davis-Smyth, HH Chen, LG Presta, N Ferrara

Patent # 8,232,372 July 31, 2012
Engineered anti-TSLP antibody
LG Presta, R De Waal Malefyt

Patent # 8,226,947 July 24, 2012
Interleukin-10 antibodies
LG Presta

Patent # 8,216,805 July 10, 2012
Knobs and holes polymeric polypeptides
PJ Carter, LG Presta, JB Ridgway

Patent # 8,212,008 Jul 3, 2012
Antibodies to CD200R

LG Presta, HM Cherwinski, JH Phillips

Patent # 8,193,319 June 5, 2012

Antibodies to IL-17A

LG Presta, EP Bowman

Patent # 8,173,779 May 8, 2012

Neutralizing human anti-IGFR antibody

Y Wang, R Greenberg, L Presta, JA Pachter, J Hailey, P Brams, D Williams,
M Srinivasan, D Feingersh

Patent # 8,163,882 April 24, 2012

Polypeptide variants with altered effector functions

LG Presta

Patent # 8,153,134 April 10, 2012

Anti-MDL-1 antibodies

MF Bigler, PG Heyworth, JH Phillips, LG Presta

Patent # 8,119,113 Feb 21, 2012

Engineered anti-IL-23R antibodies

LG Presta

Patent # 8,101,571 Jan 24, 2012

Treatment methods using NGF variants

LG Presta, R Urfer, JW Winslow

Patent # 8,075,890 Dec 13, 2011

Method for making humanized antibodies

PJ Carter, LG Presta

Patent # 8,012,482 Sept 6, 2011

Humanized anti-TGF-beta antibodies

CW Adams, N Ferrara, E Filvaroff, W Mao, LG Presta, ML Tejada

Patent # 7,951,917 May 31, 2011

Method for making multispecific antibodies having heteromultimeric and common components

WR Arathoon, PJ Carter, AM Merchant, LG Presta

Patent # 7,935,671 May 3, 2011

Pantropic neurotrophic factors

R. Urfer, LG Presta, JW Winslow

Patent # 7,910,707 Mar 27, 2011
Anti-interferon-alpha antibodies
A. Chuntharapai, JK Kim, LG Presta, T Stewart

Patent # 7,862,817 Jan 4, 2011
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CW Adams, LG Presta, M Sliwkowski

Patent # 7,851,181 Dec 14, 2010
Neutralizing human anti-IGFR antibody
Y Wang, R Greenberg, L Presta, JA Pachter, J Hailey, P Brams, D Williams, M Srinivasan, D Feingersh

Patent # 7,847,068 Dec 7, 2010
Neutralizing human anti-IGFR antibody
Y Wang, R Greenberg, L Presta, JA Pachter, J Hailey, P Brams, D Williams, M Srinivasan, D Feingersh

Patent # 7,846,443 Dec 7, 2010
Antibodies to IL-17A
LG Presta, EP Bowman

Patent # 7,807,160 Oct 5, 2010
Engineered anti-IL-23 antibodies
LG Presta, BM Beyer, RN Ingram, P Orth, Y-H Liu

Patent # 7,799,900
Immunoglobulin variants and uses thereof
CW Adams, AC Chan, CW Crowley, HB Lowman, GR Nakamura, LG Presta

Patent # 7,790,848 Sept 7, 2010
Polypeptide variants with altered effector function
LG Presta

Patent # 7,785,791 Aug 31, 2010
Polypeptide variants with altered effector function
LG Presta

Patent # 7,771,721 Aug 10, 2010
Methods for using chimeric vascular endothelial growth factor receptor proteins
T Davis-Smyth, HH Chen, LG Presta, N Ferrara

Patent # 7,741,072 June 22, 2010
Polypeptide variants
EE Idusogie, LG Presta, MG Mulkerrin

Patent # 7,695,936 April 13, 2010
Knobs and holes heteromeric polypeptides
PJ Carter, LG Presta, JB Ridgway

Patent # 7,667,021 Feb 23, 2010
Neutralizing human anti-IGFR antibody
Y. Wang, R. Greenberg, L. Presta, J.A. Pachter, J. Hailey, P. Brams, D. Williams,
M. Srinivasan, D. Feingersh

Patent # 7,662,379 Feb 16, 2010
Interleukin-10 antibodies
L.G. Presta

Patent # 7,642,228 Jan 5, 2010
Method for making heteromultimeric polypeptides
P.J. Carter, L.G. Presta, J.B. Ridgway

Patent # 7,615,383 Nov 10, 2009
Methods for treating neuropathy by agonist anti-trkC monoclonal antibodies
B. Devaux, J-A. Hongo, L.G. Presta, D.L. Shelton

Patent # 7,582,445 Sept 1, 2009
Anti-interferon-alpha antibodies
A. Chuntharapai, J.K. Kim, L.G. Presta, T. Stewart

Patent # 7,537,931 May 26, 2009
Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies
C.W. Adams, L.G. Presta, M.Sliwkowski

Patent # 7,528,233 May 5, 2009
Pantropic neurotrophic factors
R. Urfer, L.G. Presta, J.W. Winslow

Patent # 7,527,791 May 5, 2009
Humanized anti-TGFbeta antibodies
C.W. Adams, N. Ferrara, E.H. Filvaroff, W. Mao, L.G. Presta, M.L. Tejada

Patent # 7,501,122 March 10, 2009
Treatment with anti-ErbB2 antibody combinations

C.W. Adams, L.G. Presta, M. Sliwkowski

Patent # 7,498,030 March 3, 2009

Treatment with anti-ErbB2 antibodies and anti-hormonal compounds

C.W. Adams, L.G. Presta, M. Sliwkowski

Patent # 7,485,302 February 3, 2009

Treatment with anti-ErbB2 antibodies and chemotherapeutic agents

C.W. Adams, L.G. Presta, M. Sliwkowski

Patent # 7,452,863 November 18, 2008

NGF variants

L.G. Presta, R. Urfer, J.W. Winslow

Patent # 7,435,413 October 14, 2008

Anti-tissue factor antibodies with enhanced coagulant potency

D.K. Kirchhofer, D.G. Lowe, L.G. Presta

Patent # 7,416,727 August 26, 2008

Polypeptide variants with altered effector function

L.G. Presta

Patent # 7,384,632 June 10, 2008

Agonist anti-TrkC monoclonal antibodies

B. Devaux, D.L. Shelton, J.-A. Hongo, L.G. Presta

Patent # 7,375,193 May 20, 2008

Anti-VEGF antibodies

M. Baca, J.A. Wells, L.G. Presta, H.B. Lowman, Y.M. Chen

Patent # 7,371,826 May 13, 2008

Polypeptide variants with altered effector function

L.G. Presta

Patent # 7,365,166 April 29, 2008

Anti-VEGF antibodies

M. Baca, J.A. Wells, L.G. Presta, H.B. Lowman, Y.M. Chen

Patent # 7,364,731 April 29, 2008

Polypeptide variants

E.E. Idusogie, L.G. Presta, M.G. Mullkerrin

Patent # 7,351,816 April 1, 2008

Nucleic acid encoding anti-IgE antibodies
P.M. Jardieu, L.G. Presta

Patent # 7,335,742 February 26, 2008
Polypeptide variants with altered effector function
L.G. Presta

Patent # 7,332,581 February 19, 2008
Polypeptide variants with altered effector function
L.G. Presta

Patent # 7,297,775 November 20, 2007
Polypeptide variants
E.E. Idusogie, L.G. Presta, M.G. Mulkerrin

Patent # 7,297,334 November 30, 2007
Anti-VEGF antibodies
M. Baca, J.A. Wells, L.G. Presta, H.B. Lowman, Y.M. Chen

Patent 7,217,796 May 15, 2007
Neutralizing human anti-IGFR antibody
Y. Wang, R. Greenberg, L. Presta, J.A. Pachter, J. Hailey, P. Brams, D. Williams, M. Srinivasan, D. Feingersh

Patent 7,183,387 February 27, 2007
Polypeptide variants with altered effector function
L.G. Presta

Patent # 7,183,076 February 27, 2007
Method for making multispecific antibodies having heteromultimeric and common components
W.R. Arathoon, P.J. Carter, A.M. Merchant, L.G. Presta

Patent # 7,169,901 January 30, 2007
Anti-VEGF antibodies
M. Baca, J.A. Wells, L.G. Presta, H.B. Lowman, Y.M. Chen

Patent # 7,157,085 January 2, 2007
Method for treating IgE-mediated disorders
H.B. Lowman, L.G. Presta, P.M. Jardieu, J. Lowe

Patent # 7,144,983 December 5, 2006
Pantropic neurotrophic factors

R. Urfer, L.G. Presta, J. Winslow

Patent # 7,122,637 October 17, 2006
Polypeptide variants with altered effector function
L.G. Presta

Patent # 7,087,726 August 8, 2006
Anti-interferon-alpha antibodies
A. Chuntharapai, J.K. Kim, L.G. Presta, T. Stewart

Patent # 7,060,269 June 13, 2006
Anti-VEGF antibodies
M. Baca, J.A. Wells, L.G. Presta, H.B. Lowman, Y.M. Chen

Patent # 7,005,504 February 28, 2006
Antibody fragments-PEG conjugates
V. Hsei, I. Koumenis, S. Leong, L. Presta, Z. Shahrokh, G. Zapata

Patent # 6,998,253 February 14, 2006
Altered polypeptides with increased half-life
L.G. Presta, B.R. Snedecor

Patent # 6,914,129 July 5, 2005
Anti-IgE antibodies
P. M. Jardieu, L.G. Presta

Patent # 6,911,321 June 28, 2005
Non-human primate Fc receptors and methods of use
L. G. Presta, A. K. Namenuk

Patent # 6,897,294 May 24, 2005
Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
T.L. Davis-Smith, H.H. Chen, L. Presta, N. Ferrara

Patent # 6,870,033 March 22, 2005
Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
V. Hsei, I. Koumenis, S. R. Leong, L. G. Presta, Z. Shahrokh, G. A. Zapata

Patent # 6,800,738 October 5, 2004
Method for making humanized antibodies
P. J. Carter, L. G. Presta

Patent # 6,761,889 July 13, 2004
Anti-IgE antibodies
H. B. Lowman, L. G. Presta, P. M. Jardieu, J. Lowe

Patent # 6,737,056 May 18, 2004
Polypeptide variants with altered effector function
L. G. Presta

Patent # 6,723,833 April 20, 2004
Therapeutic compositions comprising anti-IgE antibodies and immunosuppressive agent
H. B. Lowman, L. G. Presta, P. M. Jardieu, J. Lowe

Patent # 6,719,971 April 13, 2004
Method for making humanized antibodies
P. J. Carter, L. G. Presta

Patent # 6,703,494 March 9, 2004
Anti-tissue factor antibodies with enhanced anticoagulant properties
D.K. Kirchhofer, D.G. Lowe, L.G. Presta

Patent # 6,703,018 March 9, 2004
Method of treatment using humanized anti-CD11a antibodies
P. M. Jardieu, L.G. Presta

Patent # 6,699,472 March 2, 2004
Method of treating allergic disorders
P. M. Jardieu, L.G. Presta

Patent # 6,685,939 February 3, 2004
Method of preventing the onset of allergic disorders
P. M. Jardieu, L.G. Presta

Patent # 6,682,735 January 27, 2004
Anti-IgE antibodies
H.B. Lowman, L.G. Presta, P.M. Jardieu, J. Lowe

Patent # 6,639,055 October 28, 2003
Method for making humanized antibodies
P. J. Carter, L.G. Presta

Patent # 6,538,124 March 25, 2003
Polypeptide variants
E. E. Idusogie, L.G. Presta, M. G. Mulkerrin

Patent # 6,528,624 March 4, 2003

Polypeptide variants

E. E. Idusogie, L.G. Presta, M. G. Mulkerrin

Patent # 6,503,728 January 7, 2003

Pantropic neurotrophic factors

R. Urfer, L.G. Presta, J.W. Winslow

Patent # 6,468,532 October 22, 2002

Methods for treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates

V. Hsei, I. Koumenis, S. Leong, L. Presta, Z. Shakrokh, G. Zapata

Patent # 6,458,355 October 1, 2002

Methods for treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates

V. Hsei, I. Koumenis, S. Leong, L. Presta, Z. Shakrokh, G. Zapata

Patent # 6,407,213 June 18, 2002

Method for making humanized antibodies

P.J. Carter, L.G. Presta

Patent # 6,383,486 May 7, 2002

Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production

T.L. Davis-Smyth, H.H. Chen, L. Presta, N. Ferrara

Patent # 6,365,373 April 2, 2002

Nucleic acids encoding NGF variants

L.G. Presta, R. Urfer, J.W. Winslow

Patent # 6,333,310 December 25, 2001

NGF variants

L.G. Presta, R. Urfer, J.W. Winslow

Patent # 6,329,509 December 11, 2001

Anti-IgE antibodies

P.M. Jardieu, L.G. Presta

Patent # 6,290,957 September 18, 2001

Anti-IgE antibodies and method for improving polypeptides.

H.B. Lowman, L.G. Presta, P.M. Jardieu, J. Lowe

Patent # 6,242,195 June 5, 2001
Methods for determining binding of an analyte to a receptor
E.E. Idusogie, M. Mulkerrin, L.G. Presta, R.L. Shields

Patent # 6,194,551 February 27, 2001
Polypeptide variants
E.E. Idusogie, L.G. Presta, M.G. Mulkerrin

Patent # 6,172,213 January 9, 2001
Anti-IgE antibodies and method of improving polypeptides
H.B. Lowman, L.G. Presta, P.M. Jardieu, J. Lowe

Patent # 6,153,189 November 28, 2000
Human trk receptors and neurotrophic factor inhibitors
L.G. Presta, D.L. Shelton, R. Urfer

Patent # 6,133,426 October 17, 2000
Humanized anti-IL-8 monoclonal antibodies
T.N. Gonzalez; S.R. Leong; L.G. Presta

Patent 6,121,022 September 19, 2000
Altered polypeptides with increased half-life
L.G. Presta, B.R. Snedecor

Patent # 6,117,980 September 12, 2000
Humanized anti-IL8 monoclonal antibodies
T.N. Gonzalez, S.R. Leong, L.G. Presta

Patent # 6,100,071 August 8, 2000
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
T.L. Davis-Smith, H.H. Chan, L.G. Presta, N. Ferrara

Patent # 6,096,871 August 1, 2000
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
L.G. Presta, B.R. Snedecor

Patent # 6,054,297 April 25, 2000
Humanized antibodies and methods for making them
P.J. Carter, L.G. Presta

Patent # 6,037,454 March 14, 2000
Humanized anti-CD11a antibodies
P.M. Jardieu, L.G. Presta

Patent # 6,037,453 March 14, 2000
Immunoglobulin variants
P.M. Jardieu, L.G. Presta

Patent # 6,027,927 February 22, 2000
Human trk receptors and neurotrophic factor inhibitors
L.G. Presta, D.L. Shelton, R. Urfer

Patent # 6,025,166 February 15, 2000
Human trk receptors and neurotrophic factor inhibitors
L.G. Presta, D.L. Shelton, R. Urfer

Patent # 6,025,158 February 15, 2000
Nucleic acids encoding humanized anti-IL8 monoclonal antibodies
T.N. Gonzalez, S.R. Leong, L.G. Presta

Patent # 5,994,514 November 30, 1999
Immunoglobulins variants
P.M.Jardieu, L.G. Presta

Patent # 5,994,511 November 30, 1999
Anti-IgE antibodies and methods of improving polypeptides
H.B. Lowman, L.G. Presta, P.J. Jardieu, J. Lowe

Patent # 5,981,480 November 9, 1999
Pantrophic neurotrophic factors
R. Urfer, L.G. Presta, J.W. Winslow

Patent # 5,965,709 October 12, 1999
IgE antagonists
L.G. Presta, P.M. Jardieu

Patent # 5,952,199 Sept. 14, 1999
Chimeric receptors as inhibitors of vascular endothelial growth factor activity, and processes for their production
T.L. Davis-Smyth, H.H. Chen, L. Presta, N. Ferrara

Patent # 5,910,574 June 8, 1999
Human trk receptors and neurotrophic factor inhibitors

L.G. Presta, D. Shelton, R. Urfer

Patent # 5,877,016 March 2, 1999
Human trk receptors and neurotrophic factor inhibitors
L.G. Presta, D. Shelton, R. Urfer

Patent # 5,869,046 Feb. 9, 1999
Altered polypeptides with increased half-life
L.G. Presta, B.R. Snedecor

Patent # 5,844,092 Dec. 1, 1998
Human Trk receptors and neurotrophic factor inhibitors
L.G. Presta, D. Shelton, R. Urfer

Patent # 5,821,337 Oct. 27, 1998
Immunoglobulin variants
P.J. Carter, L.G. Presta

Patent # 5,821,333 Oct. 13, 1998
Method for making heteromultimeric polypeptides
P.J. Carter, L.G. Presta, J.B.B. Ridgway

Patent # 5,807,706 Sept. 15, 1998
Method for making heteromultimeric polypeptides
P.J. Carter, L.G. Presta, J.B.B. Ridgway

Patent # 5,747,035 June 2, 1998
Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
L.G. Presta, B.R. Snedecor

Patent # 5,739,277 April 14, 1998
Altered polypeptides with increased half-life
L.G. Presta, B.R. Snedecor

Patent # 5,731,168 March 24, 1998
Method for making heteromultimeric polypeptides
P.J. Carter, L.G. Presta, J.B.Ridgway

Patent # 5,728,803 March 17,1998
Pantropic neurotrophic factors
L.G. Presta, R. Urfer, J. Winslow

Patent # 5,593,882 Jan. 14, 1997
L-selectin variants
D.V. Erbe, L.A. Lasky, L.G. Presta

Patent # 5,520,911 May 28, 1996
Variants of plasminogen activators and processes for their production
S. Anderson, K.M. Brady, B.A. Keyt, L.G. Presta

Patent # 5,385,732 Jan. 31, 1995
Variants of tissue plasminogen activator, compositions and methods of use for same
S. Anderson, K.M. Brady, B.A. Keyt, L.G. Presta

Patent # 5,346,824 Sept. 13, 1994
DNA molecules encoding variants of tissue plasminogen activators and expression
vectors and host thereof
S. Anderson, K.M. Brady, B.A. Keyt, L.G. Presta

Patent # 5,270,198 Dec. 14, 1993
DNA molecules encoding variants of tissue plasminogen activators, vectors, and host
cells
S. Anderson, K.M. Brady, B.A. Keyt, L.G. Presta

Patent # 5,258,180 Nov. 2, 1993
Tissue plasminogen activator having fibrin specific properties and deletion of amino
acids 466-470, compositions and methods of treatment
J.F. Gill, L.G. Presta, M.J. Zoller

Patent # 5,156,969 Oct. 20, 1992
Tissue plasminogen activator variant with deletions of amino acids 466-470 having fibrin
specific properties
J.F. Gill, L.G. Presta, M.J. Zoller

Invited Speaker:

3rd International Congress on Monoclonal Antibodies in Cancer
August, 2003 (Planning Committee member)

15th Lorne Cancer Conference
Lorne, Australia, February, 2003

Antibody-based Therapeutics for Cancer/Keystone Conference
Banff, February, 2003

2nd International Conference on Monoclonal Antibodies in Cancer
Banff, September, 2002

1st International Conference on Recombinant Antibodies
Berlin, May, 2002

Mediation and Modulation of Antibody Function -- Biochemical Society
Edinburgh, April, 2002

Advances in the Application of Monoclonal Antibodies in Clinical Oncology
Greece, June, 2001

Human Antibodies and Hybridomas Conference
Prague, April, 2001

American Association for Cancer Research Annual Meeting
New Orleans, March 2001

AAAS/National Association of Science Writers
San Francisco, February 2001

Rituxan Investigators Meeting
Washington, D.C., September, 2000

Society for Biological Therapy, 1st International Meeting
Berlin, September, 2000

European Society for Medical Oncology
Berlin, September, 2000

Recent Advances and Future Directions Using Monoclonal Antibodies for B-cell
Malignancies
Hawaii, January, 1999

Antibodies: Molecular, Cellular & Clinical Aspects
sponsored by Cancer Research Institute
New York, April, 1998

International Congress of Biochemistry and Molecular Biology
San Francisco, August, 1997

International Conference on Molecular Structural Biology

Vienna, September, 1995

Awards:

Graduate Student Teaching Award, Texas A&M University

Samuel Morris Scholar, University of Arizona, 1976

Vesto M. Slipher Scholar, University of Arizona, 1975